Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Pancreatology
- Vol. 16 (5) , 859-864
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The Incidence and Survival Rate of Population-Based Pancreatic Cancer Patients: Shanghai Cancer Registry 2004–2009PLOS ONE, 2013
- Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic AdenocarcinomaYonsei Medical Journal, 2013
- Survival in Population-based Pancreatic Cancer Patients: San Francisco Bay Area, 1995-1999American Journal of Epidemiology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal AdenocarcinomaAnnals of Surgical Oncology, 2011
- Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704Journal of Clinical Oncology, 2008
- Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?British Journal of Cancer, 2008
- CA 19-9 Response as an Early Indicator of the Effectiveness of Gemcitabine in Patients with Advanced Pancreatic CancerOncology, 2008
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markersEuropean Journal of Cancer, 1999